Skip to main content

4 Result(s)

within S J Noga Remove this filter Hematology Remove this filter

and

  1. No Access

    Article

    Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study

    This phase 1 study (Clinicaltrials.gov: NCT00507442) was conducted to determine the maximum tolerated dose (MTD) of cyclophosphamide in combination with bortezomib...

    S K Kumar, I Flinn, S J Noga, P Hari, R Rifkin, N Callander, M Bhandari… in Leukemia (2010)

  2. No Access

    Article

    High incidence of graft failure in children receiving CD34+ augmented elutriated allografts for nonmalignant diseases

    T-cell depletion of the marrow graft using counterflow centrifugal elutriation reduces the risk of graft-versus-host disease (GVHD). However, because of high rates of graft failure and relapse, elutriation alo...

    C H McDonough, D A Jacobsohn, G B Vogelsang, S J Noga… in Bone Marrow Transplantation (2003)

  3. No Access

    Chapter and Conference Paper

    Cell Manipulation and Engineering — State of the Art and Future Developments

    Within the last 5 years, the new field of somatic cell therapy (SCRx) has gone through exponential growth. This term was coined by the U.S.Food and Drug Administration (FDA) in guidance documents to encompass ...

    S. J. Noga in Cellular Engineering and Cellular Therapies (2003)

  4. No Access

    Chapter

    Induction of Autologous Graft vs Host Disease: An Immunotherapeutic Approach to Eliminate Residual Leukemia After Autologous Bone Marrow Transplantation

    Graft vs host disease (GVHD) remains a major complication following allogeneic bone marrow transplantation (BMT) [1]. The large number of peripheral blood T lymphocytes which contaminate the graft during bone ...

    S. J. Noga, A. D. Hess in Peripheral Blood Stem Cell Autografts (1993)